Ann: HL Pharma Submits Australian Import Licence Appllication, page-96

Agree in principle, but I still feel the Gelpell needs decent European sales for market acceptance here. Overseas sales of a product (market tried and tested) carries more weight than company sponsored trials. Lacklustre sales currently, have done MMJ no favours. Remember too, it's been marketed as a supplement rather than a panacea. Marketing here will be difficult too, it's not like they can advertise like Nurofen or Panadol. That said, a 'boxed' pill should be more palatable for doctors and patients alike, but many patients have difficulty swallowing, and will look for an alternative.

Compound pharmacies such as Fresh Therapeutics would be more likely to deal in oils/extracts, and I think there are opportunities for the sale and consumption of said products. I'd hate for MMJ to miss the boat here, especially when they are in the box seat with GMP Satipharm oils. All in my opinionated opinion!